Amaç: Türk hipertansiyon hastalarında kardiyovasküler risk yönetimine yönelik klinik uygulamalar ve ilgili hasta uyumu değerlendirildi. Çalışma planı: Bu girişimsel olmayan gözlemsel çalışma-ya Türkiye'deki 50 merkezden, esansiyel hipertansiyonu olan 1023 hasta (620 kadın, 403 erkek; ort. yaş 58.4±10.6) katıldı. Hastalar kesitsel ve dokuz aylık takip fazları olmak üzere iki fazda değerlendirildi. Çalışmanın kesitsel fazın-da şu veriler toplandı: Hastaların demografik özellikleri, medikal ve geçmiş öykü, kardiyovasküler risk durumu ve kardiyovasküler risk yönetimine ilişkin güncel klinik uygulamalar. Bulgular: Hipertansiyonun ortalama süresi 8.1±7.1 yıl bulundu. Beden kütle indeksi ortalaması 30.3±5.2 kg/m 2 idi. Sistolik ve diyastolik kan basınçları sırasıyla 147.8±22.4 ve 88.9±12.5 mmHg idi. On-yıllık koroner kalp hastalığı riski ve risk düzeyi erkeklerde ve eşlik eden diyabet, metabolik sendrom, renal hastalık ve/veya mikroalbuminüri varlığında belirgin olarak daha yüksek bulundu (p<0.05). Geçmiş yıla yönelik kardiyovasküler risk yönetimi değerlendirildiğin-de, hastaların %7.3'ünde kan basıncı ölçümü yapılmadığı, %15.6'sında diyet önerilmediği, %79.3'ünde kan basıncı-nın yüksek düzeylerde olduğu, antihpertansif ilaç tedavisi ve diyet önerilerine yönelik hasta uyumunun ise sırasıyla %87.7% ve %62.5 olduğu görüldü. Dislipidemi ve diabetes mellitus için de benzer bir profil vardı. Hekimlerin hastaları sigarayı bırakma, kilo verme ve fiziksel egzersiz yapmaya yöneltme çabaları tatmin edici düzeylerden çok düşük bulunurken, hastaların da bu önerilere uyumları daha da düşük düzeylerdeydi. Sonuç: Çalışmamız, diyabet, metabolik sendrom ve renal hastalık gibi yüksek risk düzeyleri ile ilişkili kardiyovasküler risk faktörleri olmasına rağmen, hipertansiyon hastalarının kardiyovasküler risk açısından yeterince değerlendirilmedi-ğini ortaya koymaktadır.
D
efined as a progressive cardiovascular syndrome arising from complex and interrelated etiologies, [1] hypertension is a potent public health problem and highly prevalent cardiovascular disease risk factor, [2] expanding rapidly in prevalence worldwide. [3, 4] In the prevention of cardiovascular events, an increased emphasis has been placed on hypertension management for global cardiovascular risk reduction, including more sophisticated risk assessment and therapeutic targeting of underlying mechanisms of CVD [5] by the established treatment guidelines. [6] [7] [8] [9] Although blood pressure values have been taken as the main variable for determining the need and type of treatment for many years, the most recent guidelines suggest that ''All patients should be classified not only in relation to the grades of hypertension, but also in terms of the total cardiovascular risk resulting from the coexistence of different risk factors, organ damage, and disease''. [7] Since the causes of CVD are multifactorial, and hypertension seldom exists as an isolated risk factor, [6] current guidelines use other risk factors in addition to BP levels to determine the global level of risk for CVD. [10] Most of the risk-assessment tools and recommendations included in major guidelines for hypertension management have relied on Framingham datasets and models. [6, 11] The most recent guidelines of the European Society of Hypertension and the European Society of Cardiology assess risk in patients with hypertension as low, moderate, high, and very high added risk. These categories correlate with an approximate absolute 10-year CVD risk of <15%, 15% to 20%, >20% to 30%, and >30%, respectively, by the Framingham risk model [12] or with an approximate absolute risk of fatal CVD of <4%, 4% to 5%, >5% to 8%, and >8%, respectively, by the SCORE charts. [13] In Turkey, Total Cardiovascular Risk Management Initiative was put into practice in collaboration with Ministry of Health, Turkish Society of Cardiology, Turkish Society of Internal Disease Specialty, Turkish Society of Neurology, Turkish Society of Endocrinology and Metabolism, and Turkish Society of Hypertension and Renal Diseases. In this program, risk scoring was based on Joint British Societies' risk scoring model published in 2005 and was modified according to the circumstances of Turkey. [14] Hypertension management consists of several components, including screening of elevated BP, lifestyle interventions, evaluation for pharmaceutical treatment, continued medical follow-up, and adherence to treatment. [15] The larger the burden of risk -patients with established CVD are among those at the highest risk-the more important it is to reach and maintain BP goals. [9] Using the broad definition, treating hypertension is treating global cardiovascular risk. For the clinician, however, the goal should be to restore components of cardiovascular risk to optimal levels to restore cardiovascular health. [16] As a matter of fact, data on the details of how physicians manage cardiovascular risk factors in the office or clinic setting are very limited. Although various cardiovascular risk factor guidelines have been promulgated, their dissemination and implementation have not been successful as desired or well studied. [17] Closure of the gap between effective interventions in research studies and clinicians' practice and the gap between what clinicians recommend to patients and what patients do at home and in their communities have been suggested to be crucial to achieve and maintain BP control. In this regard, implementing health care practices and systems that guarantee continuity of care as well as integrate technology to support clinicians' decision-making and patients' selfmanagement has been indicated to be essential. [18] The present observational study was designed to identify clinical practice in cardiovascular risk management and related patient compliance within a period of 12 months among Turkish hypertensive patients.
Study design and patients
This noninterventional, cross-sectional observational study was designed to evaluate the clinical practice of physicians working in internal medicine and cardiology clinics regarding cardiovascular risk management among Turkish hypertensive patients during a followup phase of nine months.
A total of 1023 patients (620 women, 403 men; mean age 58.4±10.6 years) from 50 centers across Turkey were included in the study. Inclusion criteria were as follows: age ≥18 years, previous diagnosis of essential hypertension, treatment with antihypertensive agents (mono or combined), previous (<3 months)
PATIENTS AND METHODS

Abbreviations:
ACEI Angiotensin converting enzyme inhibitor ARB Angiotensin receptor blocker BP Blood pressure CHD Coronary heart disease CVD Cardiovascular disease HDL High-density lipoprotein routine laboratory results for the assessment of target BP levels, and signed informed consent. Known or suspected secondary hypertension, current hospitalization or having been scheduled for hospitalization during the study period, and enrollment in another study were the main exclusion criteria.
Clinical practice and patient compliance regarding cardiovascular risk management were recorded at the time of enrollment. Coronary heart disease risk in 10 years was calculated using the NCEP/ATP III risk scoring algorithm adopted via modification of the risk prediction algorithm from the Framingham Heart Study, [2] incorporating a patient's age, total cholesterol concentration, high-density lipoprotein cholesterol concentration, smoking status, and systolic BP. [19] Taking systolic BP, total cholesterol/HDL cholesterol ratio, smoking status, and age into consideration, four levels of risk to develop CVD in 10 years were defined using risk scoring charts prepared by the Turkish Society of Cardiology based on the Framingham Study: low (<10%), moderate (10-20%), high (>20%), or very high (>30%). [19] Since the study was planned as an observational and noninterventional real-time registry, the treatment decision was left to the discretion of the physician, including patients whose BP could not be controlled with their current medication.
Data collection
Data on the following characteristics were collected: patient demographics (age, gender), physical measures (height, weight, body mass index, waist circumference), medical history (duration of hypertension, concomitant diseases, risk factors), parameters for calculation of cardiovascular risk (systolic and diastolic BP, serum levels for LDL cholesterol and HDL cholesterol, history and/or laboratory tests related to diabetes mellitus, and smoking status), past history (last 12 months) of practice patterns regarding cardiovascular risk management (physician recommendations and patient compliance related to hypertension, dyslipidemia, diabetes mellitus, smoking and other factors like obesity and exercise), and antihypertensive medications.
Statistical analysis
This study hypothesized that the study population should include a minimum of 1050 patients for the determination of risk management practice in 1-50% of the overall patient population with a 95% confidence interval and 3% error. Statistical analysis was performed using the SPSS package 12.0 for Windows. Data were expressed as mean ± standard deviation and/or percentages. Categorical and numerical variables were compared using the chi-square test and Mann-Whitney U-test, respectively. A P value of less than 0.05 was considered statistically significant.
Baseline patient characteristics
Patient demographics, physical and clinical features are given in Table 1 . The mean duration of hypertension was 8.1±7.1 years. The mean body mass index was 30.3±5.2 kg/m 2 and systolic and diastolic BP values were 147.8±22.4 and 88.9±12.5 mmHg, respectively. The most frequent cardiovascular risk factors were metabolic syndrome (44.7%), family history of CVD (40.7%), diabetes mellitus (31.1%), and left ventricular hypertrophy (31.0%) ( Table 2) . Ten-year CHD risk was 13.4±6.7%, being higher in males than in females (19.2±11.8% vs. 13.3±8.1%; p<0.001). Furthermore, the presence of diabetes (p=0.009), metabolic syndrome (p=0.005), and renal disease and/or microalbuminuria (p=0.012) significantly increased 10-year CHD risk (Table 3) .
RESULTS
Cardiovascular disease risk level was low in 34.2%, moderate in 40.8%, high in 14.4%, and very high in 10.7% of the patients (Table 4 ). The presence of diabetes mellitus, metabolic syndrome, and renal disease and/or microalbuminuria shifted the risk to the high and very high risk levels (Table 3) .
Antihypertensive and antidiabetic medications were prescribed to 80.8% and 2.4% of the patients, respectively ( Table 5 ). The most frequently used antihypertensive drugs were renin-angiotensin system blockers (ARBs and ACEIs) alone or in combination with diuretics (50.5% of all prescriptions) followed by beta-blockers (22.4%) ( Table 5) .
Cardiovascular risk management
Considering past year history of cardiovascular risk management, 7.3% of the patients did not have BP measurements; no diet was recommended to 15.6%; and 79.3% had high BP levels indicating a failure in BP control (Table 6 ). Moreover, patient compliance with antihypertensive drug treatment and dietary rec- ommendations were not as high as it should be (87.7% and 62.5%, respectively).
A similar profile was observed for dyslipidemia and diabetes mellitus: blood levels of lipids and glucose were not measured in 18.6% and 22.4% of the patients, respectively, though lipid levels were high in 56.9% and blood glucose levels were high in 35% (Table 6 ). Compliance with drug treatment was better in both dyslipidemic and diabetic patients (82.4 for lipid lowering drugs, 92.1% for oral antidiabetics and 73.9% for insulin), but lower for dietary recommendations (63.8 and 66.4%, respectively; Table 6 ).
Of 126 patients whose data were available, it was seen that the physician made effort to motivate the patient to quit smoking in only 43.7%, and patient compliance with this recommendation was very low (18.9%) ( Table 6 ). Weight and waist circumference measurements were performed in less than half of the patients (42.2%), though 55% were diagnosed to be overweight ( Table 6 ). The physicians' effort to motivate the patient to lose weight and patients' compliance were also less than 50% (Table 6 ). The profile was worse regarding physical exercise; only 28.5% of the patients declared to exercise regularly. Physicians' effort to motivate the patient to exercise was limited to 46.9%, and 39.8% of the patients followed this recommendation (Table 6 ).
This observational study was planned to provide an insight into the current trends for cardiovascular risk management in hypertensive patients. The prevalence of hypertension was previously reported to be 30% in 1990's by the TEKHARF study [20] and 31.8% in 2003 by The PatenT study [21] in Turkey. 
DISCUSSION
The PatenT study indicated that 32.2% of hypertensive patients never had their BP measured, only 40.7% were aware of their diagnosis, 31.1% were receiving pharmacologic treatment, and only 8.1% had their BP under control. [21] Therefore, it seems reasonable to expect a high cardiovascular risk in relation to poor management of hypertension, and the primary objective of the present study was to identify clinical In line with the well-documented finding that hypertension is not a mere function of a discrete BP level, but should be considered as part of a complex syndrome of pathologic changes in the vasculature and target organs, [5] metabolic syndrome, family history, diabetes mellitus, left ventricular hypertrophy, CHD, obesity, smoking, microalbuminuria, renal disease, and peripheral artery disease were the established risk factors encountered in decreasing order in our patients having essential hypertension for less than 10 years. Accordingly, 43% of the study patients had at least one of these concomitant risk factors.
Owing to higher CVD risk levels in the presence of diabetes or metabolic syndrome or renal disease/ microalbuminuria, calculation of 10-year CHD risk via the NCEP/ATP III risk scoring algorithm seems to yield a more accurate estimation of cardiovascular risk since it includes scoring of risk factors considered to be CHD risk equivalents such as diabetes mellitus, which was neglected in the Framingham risk scoring algorithm. Since patients with CHD or a CHD risk equivalent are considered to be at very high risk for developing an acute cardiovascular event, [22] the likelihood of identifying a diabetic patient to be in low CVD risk category seems to be minimized by means of 10-year CHD risk estimation. In our study population, male gender, diabetes mellitus, metabolic syndrome, and renal disease and/or microalbuminuria were significantly associated with higher scores in 10-year CHD risk estimation. Novel analytical techniques have been developed to provide more accurate risk estimates in the future. [22, 23] Despite major advances in pharmacological treatment, hypertension is an increasingly common health problem worldwide. [4] Blood pressure control in patients on antihypertensive medication has been evaluated as unsatisfactory in the United States, Canada, and other European countries, [24] with only approximately one-third of hypertensive patients achieving recommended BP goals. [5] Accordingly, the finding that 79.3% of the patients had high BP values in both genders indicates insufficient BP control in our study population.
Not only poor adherence of the physicians to the guidelines, but also poor patient compliance contributes to this failure. Patient compliance has been reported to be the leading cause of poor BP control. [25] There are reports indicating that less than one-third of the patients still take their antihypertensive drugs after one year on antihypertensive treatment, while 40%-50% change or discontinue their treatment within six months. [26] Moreover, adherence to the use of antihypertensive medications has been reported to be critical in avoiding hypertension-related morbidity, mortality, and in decreasing economic costs to patients such as the cost of additional prescriptions, emergency department visits, hospitalizations, physician office visits, and productivity losses. [27] Good treatment adherence has several benefits for both the patient and the health care system, as it is associated with improved BP control, reduced risk for adverse cardiovascular events, and reduced all-cause and hypertension-related costs. [28] All current guidelines acknowledge that ≥1 antihypertensive agent is required in most patients with hypertension to reach desired BP goals, especially <130/80 mmHg, which the newer guidelines encourage as part of an effective strategy to reduce cardiovascular risk. [29] The recent updates of the European Society of Hypertension and European Society of Cardiology guidelines acknowledge poor hypertension control rates and endorse the use of combination therapy to improve BP control [7] and a recent analysis supports the use of ACEIs, ARBs, calcium channel blockers, or thiazide-type diuretics as first-line therapy, supplemented by other antihypertensive drugs if necessary. [10] A total of 1314 drugs were used by 827 patients in the present study. In accordance with the above suggestions, the most frequently used antihypertensive drugs were ARBs and ACEIs alone or in combination with diuretics (50.5% of all prescriptions) followed by beta-blockers (22.4%).
In our study, 87.7% of the patients declared that they were using their medication properly. Tolerability profile of ARBs is likely to be higher than with combinations involving other agents, making ARBs ideal candidates for combination therapy. [28] Higher prescription rates for ARBs alone (9.7%) or in combination with diuretics (21.5%) might have a prominent role in relatively high compliance with antihypertensive medications in our population.
However, compliance rates for dietary recommendations aiming cardiovascular risk management for hypertension, dyslipidemia, and diabetes mellitus were lower, emphasizing that BP control would not reach desirable levels if patients gain weight, perform little physical activity, smoke, and take excessive alcohol even though progressively increasing doses of multiple medications are used. [30] As defined in the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) [8] and the guidelines of the World Health OrganizationInternational Society of Hypertension, [9] major lifestyle modifications are often critically important in appropriate control of underlying hypertension. [30] The role of the physician who would determine what to prescribe and would not ignore the need to convince the patient to stay on treatment is critical in improving patient adherence and persistence. [31] The findings of the present study indicate that most healthcare providers initially do impart advice for lifestyle changes, but do not follow the outcomes, resulting in lower patient compliance rates for both drug treatment and nondrug modifications.
In a previous study concerning recommendations and compliance with the DASH (Dietary Approaches to Stop Hypertension) diet in hypertensive patients, it was found that only one-fifth of the respondents were advised to go on a diet or change their eating habits and, of those, only two-thirds followed that advice. [32] In our study, dietary recommendation for losing weight was made in 44.4%, exercise was recommended in 46.9%, and the corresponding compliance rates were 48.2% and 39.8%. Indeed, there is considerable evidence for the protective effects of both physical activity and cardiorespiratory fitness on hypertension, suggesting an inverse dose-response relationship between increasing levels of physical activity and all-cause and CVD mortality. [33] Physicians have a particular opportunity to discuss changes in behaviors of their patients who have already been diagnosed with hypertension or pre-hypertension or who may be at risk for developing hypertension, and may play a significant role in the success of lifestyle changes. [34] Accordingly, physicians' advice was found to motivate patients and increase their confidence in making lifestyle changes and was shown to be a predictor of attempts to change lifestyle behaviors. [32] However, lack of time, patient noncompliance, inadequate teaching materials, lack of training in counseling, lack of knowledge, inadequate reimbursement, and low physician confidence were reported as barriers to success. [35] Additionally, many healthcare providers may not consider the time spent for counseling patients on lifestyle changes very cost-effective because of the misconception that many patients do not follow physicians' advice. This may give rise to a predilection for other interventions such as treating comorbidities and medication counseling rather than life style modifications. [32] A study comparing physicians' practices on cardiovascular disease risk factor management in France and the United States found that French primary care physicians focused more on lifestyle modifications than medication management compared with US counterparts (53% vs. 33%). [17] French physicians were reported to spend more time with their patients, rely more regularly on electronic health records, use evidence-based guidelines, and have more ''fun'' in the practice of medicine. [36] In this regard, besides an educational intervention for health care providers aiming to improve their knowledge, communication skills, and confidence for delivering advice, and thus to increase the delivery of timely and appropriate educational materials to patients, [32] the more direct incorporation of the guidelines into daily practice may be a relatively simple step in an attempt to enhance cardiovascular risk reduction. [37] In addition to physician-related factors, the asymptomatic and chronic nature of hypertension adversely affects both adherence and persistence of the patients due to the "lack" of symptoms which would otherwise remind them of their condition and the "absence" of adverse effects when medications are not taken properly. In addition, the patient's understanding of hypertension and perception of the condition may also affect adherence. If a patient is not aware of the chronic nature of the disease, or believes that it is a trivial condition, he/she would be less likely to adhere to and persist with the prescribed therapy. [28] Harmonization and communication between specialist physicians such as cardiologists and neurologists and primary care physicians who are involved in day-to-day care of patients will improve hypertension treatment in patients with a prior event. Attaining and maintaining BP goals in these patients will be an important factor in prolonging their survival and preventing premature disability. [2] To accomplish this mission, clinicians must treat hypertension in its broadest sense, in that those with the hypertension specialist designation, whether they are specialists in internal medicine, family medicine, cardiology, nephrology, endocrinology, obstetrics and gynecology, or others, must be able to deal not only with BP elevations, but also with dyslipidemia, metabolic disturbances (e.g., type 2 diabetes mellitus), and metabolic syndrome. [16] Since CVD has been and remains the leading cause of death in essentially all first-world nations for more than five decades, anyone who successfully operates a ''better mousetrap'' to address this burden should rightfully be the object of scientific admiration. [37] In conclusion, the results of this observational, noninterventional study demonstrate that hypertensive patients are not fully evaluated for cardiovascular risk, which is significantly increased in the presence of various concomitant cardiovascular risk factors such as diabetes, metabolic syndrome, and renal disease. Another striking finding on the part of hypertensive patients is that there is a considerable gap between physicians' recommendations of appropriate management and the levels of patients' compliance with both drug treatment and lifestyle modifications.
